A medication already widely used to manage type 2 diabetes and aid in weight loss may offer a surprising new benefit: reducing alcohol consumption and preventing relapse. New research published in the journal eBioMedicine demonstrates that tirzepatide, the active ingredient in the drug Mounjaro, significantly curbed alcohol intake in animal models, offering a potential pathway toward novel treatments for alcohol use disorder. The findings build on previous work showing similar effects with semaglutide, found in Ozempic and Wegovy.
The study, conducted by researchers at the University of Gothenburg in Sweden, revealed that voluntary alcohol consumption decreased by more than 50% in rats and mice treated with tirzepatide. Importantly, the drug also appeared to interrupt the cycle of relapse, a major challenge in treating alcohol use disorder. After periods of abstinence, the animals did not exhibit the increased alcohol-seeking behavior typically observed; instead, their consumption remained lower than baseline levels. This suggests tirzepatide doesn’t just reduce immediate intake, but also addresses the underlying mechanisms driving compulsive alcohol use.
“We observed clear and robust reductions in long-term alcohol consumption, binge-like drinking, and relapse-like drinking in both male and female animals,” said Christian Edvardsson, a doctoral student in pharmacology at the Sahlgrenska Academy, University of Gothenburg. “What makes this study particularly compelling is that it also provides new insight into how this class of drugs may influence the brain’s reward system.”
How Tirzepatide Impacts Brain Chemistry
Tirzepatide is unique in its mechanism of action, functioning as a dual agonist at receptors for the satiety hormones GIP and GLP-1. Initially approved for treating type 2 diabetes, its effectiveness in promoting weight loss has led to its increasing use in clinical practice. Because of its established safety profile, researchers believe tirzepatide could be a promising candidate for repurposing to address other conditions, including alcohol use disorder. The study pinpointed specific changes in brain activity that may explain the drug’s effects.
Researchers found that tirzepatide lessened the impact of alcohol on dopamine, a key neurotransmitter involved in the brain’s reward system. Alcohol triggers dopamine release, creating a pleasurable sensation that reinforces drinking behavior. By attenuating this effect, tirzepatide may reduce the reinforcing properties of alcohol, making it less appealing. This effect appears to be linked to activity in the lateral septum, a brain region crucial for motivation, reward, and relapse in both animals and humans.
Further investigation revealed alterations in histone-related proteins within the lateral septum. These proteins play a role in regulating gene expression – essentially controlling which genes are “switched on” or “off.” Changes in these proteins have been previously associated with substance use and addiction, suggesting tirzepatide may be influencing the underlying biological processes that contribute to these conditions. However, researchers emphasize that the study doesn’t prove these changes *cause* the reduction in alcohol consumption, but rather that they may be part of the complex mechanisms at play.
Building on Previous Research
This isn’t the first time researchers have explored the potential of this drug class to address alcohol use. The University of Gothenburg team previously demonstrated that semaglutide, the active ingredient in Ozempic and Wegovy, also reduced alcohol consumption in rats. That earlier research laid the groundwork for the current study, which specifically focused on tirzepatide and its broader effects.
The current study was a collaborative effort between researchers at the University of Gothenburg and colleagues at the Medical University of South Carolina. The team combined behavioral tests with detailed measurements of neurotransmitter levels and molecular analyses to gain a comprehensive understanding of how tirzepatide impacts the brain.
What’s Next for Tirzepatide and Alcohol Use Disorder?
Although these findings are promising, Elisabet Jerlhag Holm, Professor of Pharmacology at the Sahlgrenska Academy, University of Gothenburg, cautions that tirzepatide is not yet a proven treatment for alcohol use disorder. “This is not yet a new treatment for alcohol use disorder,” she stated. “But the findings reinforce the view that drugs targeting these neural systems may be relevant to investigate further as potential treatment options.”
The researchers emphasize the need for further studies, including clinical trials in humans, to determine whether tirzepatide can effectively and safely reduce alcohol consumption in people struggling with alcohol use disorder. The established safety profile of the drug offers a degree of reassurance, but rigorous testing is essential before it can be considered a viable treatment option. The potential for repurposing existing medications like tirzepatide offers a faster and more cost-effective path to developing new therapies for this widespread and challenging condition.
The ongoing research into tirzepatide and its effects on the brain’s reward system could open new avenues for understanding and treating not only alcohol use disorder, but also other addiction-related behaviors. As scientists continue to unravel the complex neurobiology of addiction, medications like Mounjaro may hold unexpected keys to recovery.
If you or someone you know is struggling with alcohol use disorder, resources are available. You can find support and information from the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 1-800-662-HELP (4357) or by visiting their website at https://www.samhsa.gov/.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
